Posted inNews and Updates
Decoding Long COVID Clinical Trials: A Patient’s Guide
Confused by Long COVID study data? Learn how to evaluate clinical trials, understand primary endpoints, and spot reliable research for PASC treatments.
Posted inNews and Updates
GLP-1 Drugs Linked to Lower Addiction Hospitalizations
New research suggests GLP-1 agonists may help reduce addiction-related hospitalizations, but findings show the benefits disappear once patients stop use.
Posted inNews and Updates
Safety Alert: Steerable Sheaths for PFA Recalled
Essential recall notice: Steerable sheaths used in PFA procedures are being pulled due to safety risks. Read the latest clinical update for providers.
Posted inNews and Updates
FDA Reports Spike in Q2 Packaging-Related Product Recalls
Recent FDA data reveals a surge in Q2 pharmaceutical and medical device recalls linked to packaging failures and labeling errors. Learn the critical impact.
Posted inNews and Updates
Kolon TissueGene Phase III Knee Trial Fails: What It Means
Kolon TissueGene’s Invossa-K fails Phase III trial for knee osteoarthritis. Learn how this clinical setback impacts the future of gene therapy treatments.
Posted inNews and Updates
CAR T-Cell Therapy Shows Promise for Rare Amyloidosis
A groundbreaking clinical trial reveals CAR T-cell therapy shows promise for treating AL amyloidosis by targeting the root cause of protein buildup.
Posted inNews and Updates
Thykamine™ Clinical Trial Approved for Pediatric Eczema
Health Canada has approved a Phase II/III clinical trial for Thykamine™ to treat pediatric atopic dermatitis in patients aged 3 months to 17 years.
Posted inNews and Updates
JAK Inhibitors for Vitiligo: Clinical Updates & Safety Data
Explore the latest clinical data on systemic JAK inhibitors for vitiligo. Discover how this emerging treatment works, its efficacy, and vital safety protocols.
Posted inNews and Updates
Eli Lilly’s $2.8 Billion Venture Into Psychedelic Research
Eli Lilly invests $2.8 billion to pioneer psychedelic research, aiming to overcome the limitations of traditional clinical trial infrastructure.
Posted inNews and Updates
iPSC Cell Therapy Shows Promise for Spinal Cord Injuries
New Phase 1 trial data reveals the safety and potential of iPSC-derived cell therapy to treat subacute spinal cord injuries and promote neural recovery.